Skip to content
Screener

EPS (Diluted) at other companies

Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Amgen logo
AmgenAMGN
$4.37+64.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.23+58.3%
Glaukos logo
GlaukosGKOS
-$0.31+8.8%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
-$1.09-28.2%
Precigen logo
PrecigenPGEN
-$0.02+88.9%

Other financials

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation

See full
Market cap$83.89B+34.8%
Enterprise value$84.13B+33.7%
P/E19.4×+5.4×
P/S5.4×+1.0×

Profitability

See full
Gross margin94.9%
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 6:52 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000872589-26-000025
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Income tax expense230.9127.1334.9223.4
Net income$1,296.9$1,391.6$2,024.1$2,200.3
Net income per share - basic$12.62$13.24$19.58$20.78
Net income per share - diluted$12.23$12.81$18.95$20.02
Weighted average shares outstanding - basic102.8105.1103.4105.9
Weighted average shares outstanding - diluted106.0108.6106.8109.9
Statements of Comprehensive Income
Net income$1,296.9$1,391.6$2,024.1$2,200.3

Item 1. Financial Statements (unaudited)

FAQ

What is Regeneron Pharmaceuticals's EPS (diluted)?
Regeneron Pharmaceuticals (REGN) reported EPS (diluted) of $12.23 in Q2 2026.
How has Regeneron Pharmaceuticals's EPS (diluted) changed year-over-year?
Regeneron Pharmaceuticals's EPS (diluted) decreased by 4.5% year-over-year, from $12.81 to $12.23.
What is the long-term trend for Regeneron Pharmaceuticals's EPS (diluted)?
Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's EPS (diluted) has grown at a -12.9% compound annual growth rate (CAGR), from $72.07 to $41.57.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Regeneron Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude